Cargando…
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective
Haemophilia A and B are rare bleeding disorders. Over the past decades, they have been transformed from debilitating diseases to manageable conditions in the Western world. However, optimizing haemophilia care remains challenging in developing countries. Several challenges and unmet needs remain in...
Autores principales: | Tomeo, Francesca, Mariz, Segundo, Brunetta, Angelo Loris, Stoyanova‐Beninska, Violeta, Penttila, Karri, Magrelli, Armando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596702/ https://www.ncbi.nlm.nih.gov/pubmed/33772837 http://dx.doi.org/10.1111/bcp.14838 |
Ejemplares similares
-
Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021) -
Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021) -
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective
por: Sheean, Maria E., et al.
Publicado: (2021) -
CAR-T State of the Art and Future Challenges, A Regulatory Perspective
por: Giorgioni, Lorenzo, et al.
Publicado: (2023) -
Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe
por: Farkas, Andreas M., et al.
Publicado: (2017)